Regulatory Compliance 7 Jan 2025 compliance, information collection, department of justice, expungement form, fbi

📜DOJ Notice on FBI Expungement Form Information Collection Activities

The CJIS Division, FBI, DOJ, will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.

Learn More
Regulatory Compliance, Environmental Regulations 7 Jan 2025 compliance, energy regulation, water quality certification, clean water act, northern states power
Compliance, Regulatory Guidance 7 Jan 2025 compliance, fda, biotechnology, genomic alterations, food animals

🧬FDA Guidance on Genomic Alterations in Food-Producing Animals

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry (GFI) #251 entitled "Heritable Intentional Genomic Alterations in Animals of Food-Producing Species for Use as Models of Disease." This draft guidance, when finalized, will set forth FDA's policy regarding heritable intentional genomic alterations (IGAs) in animals of food- producing species, such as swine and rabbits, that are intended to be marketed for use as models of human or animal disease in biomedical research under contained and controlled conditions. The draft guidance describes the conditions under which we generally may not expect developers of IGAs in animal models of disease to submit an application to FDA's Center for Veterinary Medicine (CVM) or to get our approval before marketing their animals following CVM's prior review of risk factor data.

Learn More
Compliance, Regulatory Requirements 7 Jan 2025 compliance, fda, human cells, mycobacterium tuberculosis, tissue-based products

🦠FDA Guidance on Reducing Mycobacterium Tuberculosis Transmission Risks

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for immediate implementation entitled "Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)." FDA is issuing this guidance to assist establishments that make donor eligibility determinations for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps), with recommendations for screening donors for evidence of, and risk factors for, infection with Mycobacterium tuberculosis (Mtb), the organism that causes tuberculosis. The guidance also recommends additional steps that HCT/P establishments should take to reduce risk of transmission of Mtb until such time as appropriate FDA-licensed, approved, or cleared donor screening tests are available for use to test donors for Mtb infection. The guidance identifies Mtb as a relevant communicable disease agent or disease (RCDAD) and supplements the recommendations contained in other donor eligibility guidance documents for donors of HCT/Ps. This guidance is being issued to address the urgent public health need to reduce the risk of transmission of Mtb by HCT/Ps.

Learn More
Compliance, Infrastructure Development 7 Jan 2025 compliance, aviation, faa, transportation, incorporation by reference, airspace, navigation (air), airspace modification, battle mountain

✈️FAA Proposes Airspace Modification for Battle Mountain Airport

This action proposes to modify the Class E airspace area designated as surface area, establish a Class E airspace area designated as an extension to a Class D or Class E surface area, modify Class E airspace extending upward from 700 feet above the surface of the earth, and remove Class E airspace extending upward from 1,200 feet above the surface at Battle Mountain Airport, Battle Mountain, NV. Additionally, this action proposes administrative amendments to update the airport's existing Class E airspace legal descriptions. These actions would support the safety and management of instrument flight rules (IFR) operations at the airport.

Learn More
Compliance, Regulatory, Defense 7 Jan 2025 compliance, china, business regulation, defense, national security, military

⚔️Notice of Chinese Military Companies and Its Business Implications

The Deputy Secretary of Defense has determined that the entities listed in the SUPPLEMENTARY INFORMATION section of this notice qualify as "Chinese military companies" in accordance with the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021.

Learn More
Compliance, Regulatory 7 Jan 2025 compliance, information collection, reporting requirements, federal energy regulatory commission, energy industry, electric reliability organization

⚡FERC-725 Notice

In compliance with the requirements of the Paperwork Reduction Act of 1995, the Federal Energy Regulatory Commission (Commission or FERC) is soliciting public comment on the currently approved information collection, FERC 725, Certification of Electric Reliability Organization; Procedures for Electric Reliability Standards. There were no changes made to the reporting requirements for this information collection.

Learn More
Regulatory Compliance, Trade Policy 7 Jan 2025 compliance, international trade, antidumping, trade regulations, innerspring units, us commerce department

📈Antidumping Duty Orders on Innerspring Units

As a result of these expedited sunset reviews, the U.S. Department of Commerce (Commerce) finds that revocation of the antidumping duty (AD) orders on uncovered innerspring units (innersprings) from the People's Republic of China (China), the Socialist Republic of Vietnam (Vietnam), and South Africa would be likely to lead to the continuation or recurrence of dumping at the levels indicated in the "Final Results of Sunset Reviews" section of this notice.

Learn More
Compliance, Regulatory Requirements 7 Jan 2025 compliance, fda, guidance, human cells, tissue products, sepsis

⚠️FDA Guidance to Reduce Sepsis Risk in Human Cells and Tissues

The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a final guidance for immediate implementation entitled "Recommendations To Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)." FDA is issuing this guidance to provide establishments making donor eligibility determinations with recommendations to reduce the risk of transmission of infections due to sepsis by HCT/Ps. This notice is being issued to respond to a public health safety concern and to address the urgent need for updated recommendations in making a donor eligibility determination when screening a donor for clinical evidence of sepsis and clinical signs to consider.

Learn More
Compliance, Economic Development 7 Jan 2025 compliance, energy, environmental assessment, virginia, hydroelectric project, ferc